Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 9/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602987 | 0.89 | PPARG (0.41) | PPARGTRPM8MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL3216016 | 0.78 | TRPM8 (0.42) | PPARGTRPM8MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL3211597 | 0.75 | PPARG (0.41) | PPARGTRPM8MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL4601935 | 0.74 | PPARG (0.50) | PPARGTRPM8LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3196660 | 0.74 | TRPM8 (0.43) | PPARGTRPM8MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL3214134 | 0.73 | PPARG (0.41) | PPARGTRPM8MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL4600613 | 0.71 | PPARG (0.47) | PPARGLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4601114 | 0.71 | LMNA (0.47) | PPARGLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4603056 | 0.70 | PPARG (0.46) | PPARGLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3206552 | 0.70 | PPARG (0.63) | PPARGLMNASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885TRPM8 3376/4885MRGPRX4 1727/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885TRPM8 2936/4885MRGPRX4 1455/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885TRPM8 3376/4885MRGPRX4 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.